Replimune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. 

CEO
Sushil Patel
CEOSushil Patel
Employees
479
Employees479
Headquarters
Woburn, Massachusetts
HeadquartersWoburn, Massachusetts
Founded
2015
Founded2015
Employees
479
Employees479

REPL Key Statistics

Market cap
781.96M
Market cap781.96M
Price-Earnings ratio
-2.64
Price-Earnings ratio-2.64
Dividend yield
Dividend yield
Average volume
9.99M
Average volume9.99M
High today
$10.46
High today$10.46
Low today
$9.39
Low today$9.39
Open price
$9.98
Open price$9.98
Volume
4.61M
Volume4.61M
52 Week high
$13.24
52 Week high$13.24
52 Week low
$1.50
52 Week low$1.50

Stock Snapshot

Replimune(REPL) stock is priced at $9.44, giving the company a market capitalization of 781.96M. It carries a P/E multiple of -2.64.

On 2026-06-07, Replimune(REPL) stock traded between a low of $9.39 and a high of $10.46. Shares are currently priced at $9.44, which is +0.5% above the low and -9.8% below the high.

Replimune(REPL) shares are trading with a volume of 4.61M, against a daily average of 9.99M.

During the past year, Replimune(REPL) stock moved between $1.50 at its lowest and $13.24 at its peak.

During the past year, Replimune(REPL) stock moved between $1.50 at its lowest and $13.24 at its peak.

REPL News

Benzinga 6d
Why Is Replimune Stock Gaining Monday?

REPL Stock Catalyst: RP2 Data Presentation At ASCO It enrolled 85 heavily pretreated patients with advanced solid tumors. On Sunday, the company said, RP2 mon...

Why Is Replimune Stock Gaining Monday?
Simply Wall St 6d
Replimune Group Is Up 77.0% After FDA Prioritizes RP1 Melanoma BLA Resubmission Path - Has The Bull Case Changed?

Replimune Group, Inc. recently announced that, following collaborative discussions, it has aligned with the U.S. FDA on a prioritized resubmission and review pa...

Replimune Group Is Up 77.0% After FDA Prioritizes RP1 Melanoma BLA Resubmission Path - Has The Bull Case Changed?
TipRanks 7d
Replimune presents 3-year overall survival data from IGNYTE trial

Replimune (REPL) Group presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed me...

Analyst ratings

63%

of 8 ratings
Buy
12.5%
Hold
62.5%
Sell
25%

People also own

Based on the portfolios of people who own REPL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.